Morgan Stanley analyst Judah Frommer raised the firm’s price target on Zenas BioPharma (ZBIO) to $37 from $34 and keeps an Overweight rating on the shares after the company reported its Q3 update. The “highly anticipated” Phase 3 INDIGO results in IgG4-RD expected around year-end “should offer another opportunity for positive share inflection” if obexelimab data are competitive with Amgen’s (AMGN) Uplizna, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Zenas BioPharma’s Promising Autoimmune Platform and Buy Rating Reinforced by Advancements in Obexelimab and Orelabrutinib Trials
- Zenas BioPharma, Inc.: Promising Outlook with Positive Clinical Results and Strong Financial Position Supporting Buy Rating
- Optimistic Buy Rating for Zenas BioPharma Driven by Promising Clinical Trials and Strong Financial Position
- Zenas BioPharma reports Q3 EPS ($1.22), consensus (85c)
- Zenas BioPharma price target raised to $34 from $31 at Morgan Stanley